RADIANCE 2: Difference between revisions
Jump to navigation
Jump to search
Redirecting 'RADIANCE 2' to 'Rating Atherosclerotic Disease Change By Imaging With A New Cetp Inhibitor - 2' |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{High density lipoprotein}} | |||
{{CMG}}; {{AE}} {{Rim}} | |||
==Official Title== | |||
==Objective== | |||
==Sponsor== | |||
==Timeline== | |||
{| class="wikitable" border="1" style="background:WhiteSmoke" width="40%" | |||
|- | |||
| Colspan="2" style="background:Gainsboro" align="center"|'''Timeline''' | |||
|- | |||
| Style="width:30%"| '''Start Date'''||Style="width:70%"| | |||
|- | |||
| '''End Date'''|| | |||
|- | |||
| '''Status'''|| | |||
|- | |||
|} | |||
<span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00136981.</span> | |||
==Study Description== | |||
{| class="wikitable" border="1" style="background:WhiteSmoke" width="40%" | |||
|- | |||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Description''' | |||
|- | |||
| Style="width:30%"|'''Study Type'''|| Style="width:70%"| | |||
|- | |||
| '''Study Phase''' || | |||
|- | |||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Design''' | |||
|- | |||
| '''Allocation'''|| | |||
|- | |||
| '''Endpoint'''|| | |||
|- | |||
| '''Interventional Model'''|| | |||
|- | |||
| '''Masking'''|| | |||
|- | |||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details''' | |||
|- | |||
| '''Primary Purpose'''|| | |||
|- | |||
| '''Condition'''|| | |||
|- | |||
| '''Intervention'''|| | |||
|- | |||
| '''Study Arms'''|| | |||
|- | |||
| '''Population Size'''|| | |||
|- | |||
|} | |||
<span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00136981.</span> | |||
==Eligibility Criteria== | |||
===Inclusion Criteria=== | |||
===Exclusion Criteria=== | |||
==Outcomes== | |||
===Primary Outcomes=== | |||
==Publications== | |||
===Results=== | |||
===Conclusion=== | |||
Pending | |||
==References== | |||
{{Reflist|2}} | |||
{{Lipopedia}} | |||
[[Category:Lipopedia]] | |||
[[Category:HDL]] | |||
[[Category:Clinical trials]] | |||
[[Category:HDLpedia]] | |||
Revision as of 16:00, 18 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
RADIANCE 2 On the Web |
|
American Roentgen Ray Society Images of RADIANCE 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Official Title
Objective
Sponsor
Timeline
| Timeline | |
| Start Date | |
| End Date | |
| Status | |
The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00136981.
Study Description
| Study Description | |
| Study Type | |
| Study Phase | |
| Study Design | |
| Allocation | |
| Endpoint | |
| Interventional Model | |
| Masking | |
| Study Details | |
| Primary Purpose | |
| Condition | |
| Intervention | |
| Study Arms | |
| Population Size | |
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00136981.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Outcomes
Primary Outcomes
Publications
Results
Conclusion
Pending